Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katherine Harris
Observed name:
Katherine E. Harris
Observed institution:
Massachusetts General Hospital
ORCID:
0009-0002-3075-1430
Observed ORCID:
0009-0002-3075-1430
OpenAlex ID:
A5082261268
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2023
·
Andreas Varkaris
, Ermira Pazolli
, et al.
·
Cancer Discovery
·
112
PDF
Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Data from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S4 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Supplemental Text from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S4 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024
·
Andreas Varkaris
, Ermira Pazolli
, et al.
Show more works
View as search
Works count:
30
Citation count:
112
H-index:
1
I10-index:
1
Year
Topic
Type
